Published in Drug Metab Dispos on June 27, 2013
Systemic exposure to menthol following administration of peppermint oil to paediatric patients. BMJ Open (2015) 0.76
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Drug Des Devel Ther (2014) 0.75
Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation. J Clin Pharmacol (2016) 0.75
Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol (2017) 0.75
Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med (2003) 7.51
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther (1994) 5.22
Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol (2009) 4.16
The isolation and identification of the urinary oxidative metabolites of metronidazole in man. J Pharmacol Exp Ther (1968) 2.43
Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 2.25
Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet (1999) 1.97
Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther (1996) 1.74
The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry (1990) 1.62
Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol (2001) 1.53
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos (2010) 1.50
Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol (2007) 1.36
Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics (2009) 1.28
Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos (2007) 1.27
Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos (2007) 1.24
Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother (2012) 1.23
Metronidazole population pharmacokinetics in preterm neonates using dried blood-spot sampling. Pediatrics (2011) 1.18
Mechanisms of selective toxicity of metronidazole and other nitroimidazole drugs. Br J Vener Dis (1980) 1.17
Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J (1990) 1.14
Pharmacokinetics of intravenous metronidazole in neonates. J Pediatr Surg (1988) 1.13
Liquid chromatographic assay for metronidazole and tinidazole: pharmacokinetic and metabolic studies in human subjects. Antimicrob Agents Chemother (1981) 1.10
CYP2A6: a human coumarin 7-hydroxylase. Toxicology (2000) 1.10
Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet (2011) 1.09
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. Antimicrob Agents Chemother (1982) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol Biopharm (1978) 1.03
Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells. Biochim Biophys Acta (2010) 0.96
Pharmacokinetics and tissue distribution of metronidazole in the new born infant. J Pediatr (1982) 0.93
Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther (2006) 0.92
PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenet Genomics (2012) 0.92
A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci (1997) 0.92
Characterization of metronidazole metabolism by human liver microsomes. Biochem Pharmacol (1991) 0.90
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther (2007) 0.87
Disposition kinetics of metronidazole in children. Eur J Clin Pharmacol (1983) 0.86
Expression of biotransformation enzymes in human fetal olfactory mucosa: potential roles in developmental toxicity. Toxicol Appl Pharmacol (2000) 0.86
Challenges for drug studies in children: CYP3A phenotyping as example. Drug Discov Today (2008) 0.83
Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos (2005) 0.83
Intravenous metronidazole in the newborn. Arch Dis Child (1983) 0.82
Human CYPs: in vivo and clinical aspects. Drug Metab Rev (2002) 0.80
Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. J Chromatogr A (2008) 0.78
Single dose prophylaxis with metronidazole in infants during abdominal surgery: a pharmacokinetic study. Eur J Clin Pharmacol (1986) 0.77
A comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of benzoylmetronidazole and metronidazole. Br J Clin Pharmacol (1982) 0.76
Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol (2011) 1.64
Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis (2012) 1.63
Use of the complete blood cell count in late-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.63
Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J (2012) 1.53
No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J (2015) 1.53
Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther (2004) 1.51
Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther (2003) 1.42
The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J (2006) 1.36
Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J (2009) 1.33
Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J (2011) 1.30
The status of paediatric medicines initiatives around the world--What has happened and what has not? Eur J Clin Pharmacol (2011) 1.26
Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol (2010) 1.24
Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin Pharmacol Ther (2003) 1.22
Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol (2011) 1.19
Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med (2005) 1.19
Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J (2011) 1.14
Pediatric cardiovascular drug trials, lessons learned. J Cardiovasc Pharmacol (2011) 1.13
Cytokines and toxicity in acetaminophen overdose. J Clin Pharmacol (2005) 1.13
Developmental pharmacokinetics. Handb Exp Pharmacol (2011) 1.09
Use of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J (2012) 1.07
Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother (2010) 1.06
Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J (2013) 1.06
Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol (2004) 1.02
Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J (2013) 1.02
The bioequivalence of nizatidine (Axid) in two extemporaneously and one commercially prepared oral liquid formulations compared with capsule. J Clin Pharmacol (2003) 1.00
Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J (2008) 0.99
Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol (2009) 0.99
Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos (2006) 0.98
Association of the histamine N-methyltransferase C314T (Thr105Ile) polymorphism with atopic dermatitis in Caucasian children. Pharmacotherapy (2008) 0.96
Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr (2004) 0.96
Proton pump inhibitors in pediatrics : mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics. Paediatr Drugs (2013) 0.95
Pharmacokinetics of rifapentine in children. Pediatr Infect Dis J (2006) 0.93
Targeted liquid chromatography-mass spectrometry analysis of serum acylcarnitines in acetaminophen toxicity in children. Biomark Med (2014) 0.93
Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant. Paediatr Drugs (2011) 0.91
Beyond biomarkers: an opportunity to address the 'pharmacodynamic gap' in pediatric drug development. Biomark Med (2010) 0.91
Levofloxacin pharmacokinetics in children. J Clin Pharmacol (2005) 0.91
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J (2012) 0.90
Pharmacokinetics of intravenously administered azithromycin in pediatric patients. Pediatr Infect Dis J (2005) 0.89
Developmental pharmacogenomics. Paediatr Anaesth (2011) 0.89
Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res (2006) 0.89
Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother (2011) 0.87
Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. Pediatr Crit Care Med (2013) 0.86
Group B Streptococcus and Escherichia coli infections in the intensive care nursery in the era of intrapartum antibiotic prophylaxis. Pediatr Infect Dis J (2013) 0.86
Population pharmacokinetics of intravenous acyclovir in preterm and term infants. Pediatr Infect Dis J (2014) 0.85
Pharmacokinetics of antifungal agents in children. Early Hum Dev (2011) 0.85
Sildenafil exposure and hemodynamic effect after Fontan surgery. Pediatr Crit Care Med (2014) 0.85
Use of healthy children as volunteers in drug studies: the ethical debate. Clin Pharmacol Ther (2003) 0.84
Validation of an improved pediatric weight estimation strategy. J Pediatr Pharmacol Ther (2013) 0.84
Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol (2013) 0.84
Late-onset bloodstream infections in hospitalized term infants. Pediatr Infect Dis J (2014) 0.84
Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol (2011) 0.83
Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J (2012) 0.83
Pharmacokinetics of gatifloxacin in infants and children. Antimicrob Agents Chemother (2005) 0.83
Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother (2007) 0.83
The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin (2006) 0.82
Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections. Pediatr Infect Dis J (2014) 0.82
Developmental pharmacokinetics and pharmacodynamics of nizatidine. J Pediatr Gastroenterol Nutr (2004) 0.81
Delayed diagnosis of penicillin-resistant Streptococcus mitis endocarditis following single-dose amoxicillin prophylaxis in a child. Clin Pediatr (Phila) (2004) 0.81
Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol (2014) 0.81
Assessment of histamine pharmacodynamics by microvasculature response of histamine using histamine iontophoresis laser Doppler flowimetry. J Clin Pharmacol (2009) 0.81
Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents. Pediatr Infect Dis J (2010) 0.80
Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease. J Clin Pharmacol (2014) 0.80
Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin Pharmacol Ther (2004) 0.80
Oral prucalopride in children with functional constipation. J Pediatr Gastroenterol Nutr (2013) 0.80
Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Pediatr Infect Dis J (2012) 0.80
Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. Obstet Gynecol (2015) 0.79
Very late onset infections in the neonatal intensive care unit. Early Hum Dev (2011) 0.79
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol (2010) 0.79
Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis. J Clin Pharmacol (2011) 0.79
Single-dose pharmacokinetics of roflumilast in children and adolescents. J Clin Pharmacol (2008) 0.79
Risk factors for invasive candidiasis in infants >1500 g birth weight. Pediatr Infect Dis J (2013) 0.79
Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole. Curr Drug Metab (2013) 0.79
Availability of Oral Formulations Labeled for Use in Young Children in Serbia, Germany and the USA. Curr Pharm Des (2015) 0.78
American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra. Clin Pharmacol Ther (2003) 0.78
Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. Magn Reson Imaging (2008) 0.78
Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol (2004) 0.78
Recent Advances in the Detection of Neonatal Candidiasis. Curr Fungal Infect Rep (2010) 0.78
Population pharmacokinetic model for gatifloxacin in pediatric patients. Antimicrob Agents Chemother (2007) 0.78
Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health. Expert Rev Clin Pharmacol (2012) 0.78
Pharmacokinetics and Safety of Micafungin in Infants Supported With Extracorporeal Membrane Oxygenation. Pediatr Infect Dis J (2016) 0.77
Pharmacodynamics of intravenous and oral midazolam in preterm infants. Clin Drug Investig (2003) 0.77
Echinocandins for the nursery: an update. Curr Drug Metab (2013) 0.77
Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone replacement. Clin Ther (2008) 0.77
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs (2014) 0.77
Pharmacokinetic studies in infants using minimal-risk study designs. Curr Clin Pharmacol (2014) 0.77
Treatment strategies for methicillin-resistant Staphylococcus aureus infections in pediatrics. Paediatr Drugs (2008) 0.76
Advances in the treatment of invasive neonatal candidiasis. Expert Opin Pharmacother (2015) 0.76
Pharmacokinetics of famotidine in infants. Clin Pharmacokinet (2005) 0.76
Outcomes of catheter-associated infections in pediatric patients with short bowel syndrome. J Pediatr Gastroenterol Nutr (2010) 0.76
Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis. J Clin Pharmacol (2014) 0.76
Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia. Ther Drug Monit (2014) 0.75
Predictors of positive cerebrospinal fluid cultures in infants with bacteremia. Pediatr Infect Dis J (2014) 0.75
Acetaminophen poisoning in children: treat early and long enough. J Pediatr (2002) 0.75
A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation. Ther Drug Monit (2017) 0.75
Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients. Ther Drug Monit (2016) 0.75
Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach. Clin Neuropharmacol (2016) 0.75
Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine. Ther Drug Monit (2016) 0.75